Skip to content

GenSight Biologics receives FDA Orphan Drug Designation for GS030 in Retinitis Pigmentosa

Paris, France, 31 January 2017 – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the Company’s product candidate GS030 for the treatment of retinitis pigmentosa.

Please find the full PDF press release attached.

GenSight Biologics

Thomas Gidoin

Chief Financial Officer

+33 (0)1 76 21 72 20


Investor Relations

Florent Alba

+33 (0)1 44 71 98 55

Rooney Partners

Media Relations

Marion Janic


Source: Gensight